(20S)-23,23-Difluoro-Methylene-19-Nor-Bishomopregnacalciferol-Vitamin D Analogs
1 Assignment
0 Petitions
Accused Products
Abstract
This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
-
Citations
92 Claims
- 1. A compound having the formula:
-
8. (20S)-23,23-difluoro-1α
- -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula;
- -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula;
-
9. A pharmaceutical composition containing an effective amount of (20S)-23,23-difluoro-1α
- -hydroxy-2-methylene-19-nor-bishomopregnacalciferol together with a pharmaceutically acceptable excipient.
- View Dependent Claims (10, 11)
- 12. A method of treating psoriasis comprising administering to a subject with psoriasis an effective amount of a compound having the formula:
- 22. A method of treating a disease selected from the group consisting of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer comprising administering to a subject with said disease an effective amount of a compound having the formula:
- 31. A method of treating an autoimmune disease selected from the group consisting of multiple sclerosis, lupus, diabetes mellitus, host versus graft rejection, and rejection of organ transplants, comprising administering to a subject with said disease an effective amount of a compound having the formula:
- 40. A method of treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, asthma, and inflammatory bowel diseases, comprising administering to a subject with said disease an effective amount of a compound having the formula:
- 49. A method of treating a skin condition selected from the group consisting of wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration and insufficient sebum secretion which comprises administering to a subject with said skin condition an effective amount of a compound having the formula:
- 59. A method of treating renal osteodystrophy comprising administering to a subject with renal osteodystrophy an effective amount of a compound having the formula:
- 68. A method of treating or preventing obesity of an animal, inhibiting adipocyte differentiation, inhibiting SCD-1 gene transcription, and/or reducing body fat in an animal comprising administering to an animal in need thereof an effective amount of a compound having the formula
- 80. A method of treating secondary hyperparathyroidism comprising administering to a subject with secondary hyperparathyroidism an effective amount of a compound having the formula:
-
91. A compound having the formula:
-
92. A compound having the formula:
Specification